Wednesday, May 28th 11:00-12:00pm ET 

CAR-T Therapies:  After Seven Years, the Results are In, and the Debate Isn’t Over

11:00 – 11:05 am       

Introduction

Sara Demy, Founder & CEO, Demy-Colton

Steve Brozak, DMH, President and Co-founder, WBB Securities

11:05 – 11:10 am       

Understanding the Shortcomings of CAR-T Therapy

Helen Heslop, MD, Professor, Department of Medicine & Pediatrics and Director, Center for Cell and Gene Therapy, Baylor College of Medicine

 11:10 – 11:15 am       

Overcoming the Current Limitations of CAR-T Therapy

Malcolm Brenner, MD, PhD, Professor, Center for Cell & Gene Therapy and Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine

 11:15 – 11:20 am       

MAR-T Cells as a Novel Approach to Address Unmet Needs

Juan Vera, MD, President & CEO, Marker Therapeutics

 11:20 – 11:50 am       

Roundtable Discussion

Moderator

Richard Marfuggi, MD, DMH, WBB Research Institute

Panelists:

Malcolm Brenner, MD, PhD, Professor, Center for Cell & Gene Therapy and Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine

Helen Heslop, MD, Professor, Department of Medicine & Pediatrics and Director, Center for Cell and Gene Therapy, Baylor College of Medicine

Manali Kamdar, MD, Associate Professor of Medicine and Clinical Director of Lymphoma Services, University of Colorado

Geoffrey Shouse, DO, PhD, Hematologist-Oncologist & Researcher, City of Hope

Juan Vera, MD, President & CEO, Marker Therapeutics

 11:50 – 12:00 pm        

Q&A